Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

This article provides nomenclature recommendations developed by an international
workgroup to increase transparency and standardization of pharmacogenetic (PGx) result …

Major depressive disorders are prevalent conditions with limited treatment response and
remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants …

Psychiatric genomics is providing insights into the nature of psychiatric conditions that in
time should identify new drug targets and improve patient care. Less attention has been paid …

An important component of precision medicine—the use of whole-genome sequencing
(WGS) to guide lifelong healthcare—is electronic decision support to inform drug choice and …

In spite of promising preclinical results there is a decreasing number of new registered
medications in major depression. The main reason behind this fact is the lack of confirmation …

The number of clinically relevant gene‐based guidelines and recommendations pertaining
to drug prescribing continues to grow. Incorporating gene–drug interaction information into …

Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …

The enormous successes in the genetics and genomics of many diseases have provided the
basis for the advancement of precision medicine. Thus, the detection of genetic variants …